Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | GLP1R | P43220 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951953 | 1.00 | OTC (0.50) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL1953200 | 0.99 | OTC (0.49) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL30409031 | 0.99 | OTC (0.49) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL24788157 | 0.96 | OTC (0.47) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL24788082 | 0.91 | GLP1R (0.45) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL2509381 | 0.90 | DDAH1 (0.43) | OTCDDAH1NOD1TSHRNOS2 | |
| SCHEMBL13585793 | 0.90 | DDAH1 (0.43) | OTCDDAH1NOD1TSHRNOS2 | |
| SCHEMBL3043120 | 0.89 | DDAH1 (0.43) | OTCDDAH1GLP1RTSHRNOS2 | |
| SCHEMBL24229748 | 0.88 | OTC (0.49) | OTCDDAH1NOD1GLP1RTSHR | |
| SCHEMBL21738833 | 0.88 | OTC (0.49) | OTCDDAH1NOD1GLP1RTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-3184540-A1 | SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF | Yafei Shanghai Biolog Medicine Science& Technology (CN) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | CD4, MET, TNFSF10 | OTC 4145/4885DDAH1 3230/4885NOD1 558/4885 |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | MET, ARG1, CD4 | OTC 4204/4885DDAH1 1837/4885NOD1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.